Elevation Oncology Stock Alpha and Beta Analysis
| ELEV Stock | USD 0.50 0.01 1.96% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Elevation Oncology. It also helps investors analyze the systematic and unsystematic risks associated with investing in Elevation Oncology over a specified time horizon. Remember, high Elevation Oncology's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Elevation Oncology's market risk premium analysis include:
Beta 1.24 | Alpha 0.15 | Risk 6.31 | Sharpe Ratio (0.03) | Expected Return (0.19) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Elevation |
Elevation Oncology Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Elevation Oncology market risk premium is the additional return an investor will receive from holding Elevation Oncology long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Elevation Oncology. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Elevation Oncology's performance over market.| α | 0.15 | β | 1.24 |
Elevation Oncology expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Elevation Oncology's Buy-and-hold return. Our buy-and-hold chart shows how Elevation Oncology performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Elevation Oncology Market Price Analysis
Market price analysis indicators help investors to evaluate how Elevation Oncology stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Elevation Oncology shares will generate the highest return on investment. By understating and applying Elevation Oncology stock market price indicators, traders can identify Elevation Oncology position entry and exit signals to maximize returns.
Elevation Oncology Return and Market Media
The median price of Elevation Oncology for the period between Fri, Dec 13, 2024 and Thu, Mar 13, 2025 is 0.63 with a coefficient of variation of 12.74. The daily time series for the period is distributed with a sample standard deviation of 0.08, arithmetic mean of 0.63, and mean deviation of 0.06. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Elevation Oncology Licenses ADC Technology from Synaffix to Drive Pipeline Expansion | 12/12/2024 |
2 | Disposition of 12563 shares by Joseph Ferra of Elevation Oncology subject to Rule 16b-3 | 12/16/2024 |
3 | Elevation Oncology Given Market Outperform Rating at JMP Securities | 12/20/2024 |
4 | Elevation Oncology Receives Buy Rating from HC Wainwright | 01/15/2025 |
5 | Goldman Sachs Group Inc. Reduces Stake in Elevation Oncology Inc. | 02/06/2025 |
6 | Disposition of 25000 shares by Joseph Ferra of Elevation Oncology subject to Rule 16b-3 | 02/14/2025 |
7 | Aadi Bioscience Appoints David Dornan, PhD, as Chief Scientific Officer | 02/18/2025 |
8 | Disposition of 9211 shares by Joseph Ferra of Elevation Oncology at 0.6717 subject to Rule 16b-3 | 02/19/2025 |
9 | Acquisition by Carruthers R Michael of 31238 shares of Elevation Oncology at 1.47 subject to Rule 16b-3 | 02/26/2025 |
10 | Elevation Oncology GAAP EPS of -0.18 beats by 0.04 | 03/06/2025 |
About Elevation Oncology Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Elevation or other stocks. Alpha measures the amount that position in Elevation Oncology has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Current Ratio | 5.93 | 21.22 | 21.21 | 10.73 | Net Debt To EBITDA | 0.17 | 0.46 | 0.41 | 0.39 |
Elevation Oncology Upcoming Company Events
As portrayed in its financial statements, the presentation of Elevation Oncology's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Elevation Oncology's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Elevation Oncology's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Elevation Oncology. Please utilize our Beneish M Score to check the likelihood of Elevation Oncology's management manipulating its earnings.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Elevation Oncology
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Elevation Stock Analysis
When running Elevation Oncology's price analysis, check to measure Elevation Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elevation Oncology is operating at the current time. Most of Elevation Oncology's value examination focuses on studying past and present price action to predict the probability of Elevation Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elevation Oncology's price. Additionally, you may evaluate how the addition of Elevation Oncology to your portfolios can decrease your overall portfolio volatility.